Here we show that BMSCs drive resistance against the mainstream chemotherapeutics AraC + DnR with the CD34+/CD38− cells, representative of an LSC-enriched population, displaying higher resistance than the AML blasts. This evidence concerns the gene CD34 and acute myeloid leukemia.